Amarin Corp Plcuk (AMRN) Cash from Financing Activities (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Cash from Financing Activities of -$247000.0 for Q2 2026, up 62.75% year-over-year from -$151771.1 in Q2 2025, and up 85.36% quarter-over-quarter from -$1.7 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Cash from Financing Activities for 17 consecutive years, with -$247000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 62.75% year-over-year to -$247000.0; the TTM figure through Jun 2026 stood at -$2.2 million (down 19.26% YoY), while the FY2025 annual figure was -$2.0 million, down 40.96% from the prior year.
- Cash from Financing Activities climbed to -$247000.0 in Q2 2026 per AMRN's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $364000.0 in Q1 2023 and bottomed at -$1.7 million in Q1 2026.
- Historically, Cash from Financing Activities has averaged -$308888.9 across 5 years, with a median of -$112000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 172.08% — and 2025, when it sank 2050.0%.
- Amarin Corp Plc\Uk's Cash from Financing Activities stood at $38000.0 in 2022, then soared by 118.42% to $83000.0 in 2023, then plunged by 79.52% to $17000.0 in 2024, then slumped by 123.53% to -$4000.0 in 2025, then sank by 6075.0% to -$247000.0 in 2026.
- Business Quant data shows AMRN's Cash from Financing Activities at -$247000.0 in Q2 2026, -$1.7 million in Q1 2026, and -$4000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -3.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -1.48 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 2.34 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -3.66 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | -247,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -247,000.00 |
| Jun 30, 2026 | -247,000.00 |
| Mar 31, 2026 | -1.69 Mn |
| Mar 31, 2026 | -1.69 Mn |
| Dec 31, 2025 | -4,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Sep 30, 2025 | -248,000.00 |
| Sep 30, 2025 | -248,000.00 |
| Jun 30, 2025 | -663,000.00 |
| Jun 30, 2025 | -663,000.00 |
| Mar 31, 2025 | -1.12 Mn |
| Mar 31, 2025 | -1.12 Mn |
| Dec 31, 2024 | 17,000.00 |
| Dec 31, 2024 | 17,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Jun 30, 2024 | 34,000.00 |
| Jun 30, 2024 | 34,000.00 |
| Mar 31, 2024 | -1.43 Mn |
| Mar 31, 2024 | -1.43 Mn |